FWM
NKTR icon

Frontier Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Frontier Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$46K Hold
800
– – ﹤0.01% 383
2022
Q1 		$69K Hold
800
– – ﹤0.01% 393
2021
Q4 		$162K Buy
+800
New +$174K 0.01% 409

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Frontier Wealth Management's NKTR Position: Q2 2022 in Review

Frontier Wealth Management held its Nektar Therapeutics (NKTR) position steady in Q2 2022 at 800 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

Frontier Wealth Management first reported a position in NKTR in Q4 2021 and has held it in 3 quarters since. The position peaked at $162K in Q4 2021. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • Frontier Wealth Management held 800 shares of Nektar Therapeutics worth $46K as of Q2 2022.
  • Frontier Wealth Management left its Nektar Therapeutics share count unchanged in Q2 2022.
  • Nektar Therapeutics made up ﹤0.01% of Frontier Wealth Management's portfolio in Q2 2022, its #383 holding.
  • Frontier Wealth Management first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • Frontier Wealth Management's Nektar Therapeutics position peaked at $162K in Q4 2021.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Frontier Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.